Navigation Links
Dr. P Set - Human Fetal Normal Tissue: Umbilical Cord from BioChain

ProductsDr. P Set - Human Fetal Normal Tissue: Umbilical Cord from BioChain
Company BioChain
Item Dr. P Set - Human Fetal Normal Tissue: Umbilical Cord
Price $389.00
Description Dr. P Set from different human fetal normal tissues are available. More organs maybe available upon request. Customers can choose any two items from the whole set, and pay 70% of the whole set price. All Dr. P Set products are for research use only.
Info BioChainBioChain
BioChain Institute, Inc.
3517 Breakwater Avenue
Hayward, CA 94545 USA



Call BioChain to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-510-342-5324
Customer Service: 510.783.8588
Fax Number: 510.783.5386
Web Site: http://www.biochain.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Mouse Anti-Human S-100 alpha/beta chain Monoclonal Antibody, Unconjugated, Clone 8B10 from Santa Cruz Biotechnology, Inc.
2. Rabbit Anti-Human Vitamin K-dependent Protein S (PROS1) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
3. Rapid-Screen Arrayed cDNA Library Panels Master Plates -Human Placenta from OriGene Technologies
4. Rapid-Screen Arrayed cDNA Library Panels Master Plates -Human Heart from OriGene Technologies
5. Mouse Anti-Human Complement factor B Monoclonal Antibody, Unconjugated, Clone 9B6 from AntibodyShop A/S
6. Mouse Anti-Human Choriongonadotropin (hCG) Monoclonal Antibody, Unconjugated, Clone 5F10 from AntibodyShop A/S
7. Mouse Anti-Human Procollagen type I C-terminal propeptide (PICP) Monoclonal Antibody, Unconjugated from AntibodyShop A/S
8. Mouse Anti-Human Acetylcholinesterase, brain (AChE) Monoclonal Antibody, Unconjugated, Clone 12B4 from AntibodyShop A/S
9. Mouse Anti-Human a1-Antitrypsin (alpha-1 AT) Monoclonal Antibody, Unconjugated, Clone 4E5 from AntibodyShop A/S
10. pMIR-hU6-Luc, Human U6 Luciferase Control Vector from Mirus Bio Corporation
11. Human and Mouse RAR Neutralizing Peptide from ABR-Affinity BioReagents
Recombinant Rat Fas Ligand/TNFSF6...
Blimp-1 (H-150)...
... ATPase α-1, clone C464.6 GenBank ... Purified Na + /K + ATPase ... outer medulla Formulation: 0.1M Tris-glycine, pH 7.4, ... Assurance: routinely evaluated in immunoblot on rat ...
Immunogen: Purified native p24 from strain IIIB. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products:
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... than 70 researchers across the globe has uncovered nine ... lead to learning disabilities. The international team studied almost ... disabilities - the largest screen of this type ever ... approximately 1𔃀% of X chromosome genes, when knocked-out, have ...
... for places that can soak up carbon dioxide from the ... gas include the oceans and the enormous trees of tropical ... research now suggests they can store more carbon than previously ... and present-day datasets, Jeanine Rhemtulla of McGill University and David ...
... Five-hundred years ago, Ponce de Leon combed the swamps of ... the 2009 ASBMB Annual Meeting in New Orleans (held in ... exciting talks centering on the new molecular "fountain of youth," ... of longevity may still be a long time away, the ...
Cached Biology News:The genetic X-factor 2The genetic X-factor 3Study reveals potential to amass more carbon in eastern North American forests 2Study reveals potential to amass more carbon in eastern North American forests 3ASBMB Annual Meeting to feature talks on the biochemistry of aging 2ASBMB Annual Meeting to feature talks on the biochemistry of aging 3
(Date:7/28/2015)... July 28, 2015 Deerfield Management Company, L.P. ... Fund, L.P., which will invest in groundbreaking advancements in ... diseases, cancer, and orphan diseases. The venture capital fund ... therapeutics are developed and improve the way healthcare is ... the largest healthcare-focused venture funds in the sector, will ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix Inc. ... 1 clinical trial with MMI-0100, a first-in-class inhibitor ... developed for pulmonary disorders characterized by inflammation and ... United Kingdom , is a double-blind, two-way ... the safety and tolerability of MMI-0100 when given ...
(Date:7/28/2015)... 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... has granted to German life sciences entrepreneurs with ... commercialization of biotechnology (collectively, the "Optionee"), an option ... tumor vaccine technology (the "Technology"), including AEZS-120, the ... is ready to enter a Phase 1 clinical ...
(Date:7/28/2015)... 2015  Faced with increasing challenges such as ... than symptomatic, the global healthcare industry today is ... of curing or significantly changing the course of ... towards regenerative medicine as a viable alternative. ... human health with the potential to resolve unmet ...
Breaking Biology Technology:Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5